Evidence Refuting the Existence of Autoimmune/Autoinflammatory Syndrome Induced by Adjuvants (ASIA)

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Standard

Evidence Refuting the Existence of Autoimmune/Autoinflammatory Syndrome Induced by Adjuvants (ASIA). / Ameratunga, Rohan; Gillis, David; Gold, Michael; Linneberg, Allan; Elwood, J. Mark.

I: The Journal of Allergy and Clinical Immunology: In Practice, Bind 5, Nr. 6, 2017, s. 1551-1555.e1.

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Harvard

Ameratunga, R, Gillis, D, Gold, M, Linneberg, A & Elwood, JM 2017, 'Evidence Refuting the Existence of Autoimmune/Autoinflammatory Syndrome Induced by Adjuvants (ASIA)', The Journal of Allergy and Clinical Immunology: In Practice, bind 5, nr. 6, s. 1551-1555.e1. https://doi.org/10.1016/j.jaip.2017.06.033

APA

Ameratunga, R., Gillis, D., Gold, M., Linneberg, A., & Elwood, J. M. (2017). Evidence Refuting the Existence of Autoimmune/Autoinflammatory Syndrome Induced by Adjuvants (ASIA). The Journal of Allergy and Clinical Immunology: In Practice, 5(6), 1551-1555.e1. https://doi.org/10.1016/j.jaip.2017.06.033

Vancouver

Ameratunga R, Gillis D, Gold M, Linneberg A, Elwood JM. Evidence Refuting the Existence of Autoimmune/Autoinflammatory Syndrome Induced by Adjuvants (ASIA). The Journal of Allergy and Clinical Immunology: In Practice. 2017;5(6):1551-1555.e1. https://doi.org/10.1016/j.jaip.2017.06.033

Author

Ameratunga, Rohan ; Gillis, David ; Gold, Michael ; Linneberg, Allan ; Elwood, J. Mark. / Evidence Refuting the Existence of Autoimmune/Autoinflammatory Syndrome Induced by Adjuvants (ASIA). I: The Journal of Allergy and Clinical Immunology: In Practice. 2017 ; Bind 5, Nr. 6. s. 1551-1555.e1.

Bibtex

@article{8b905769ba8847728646743a2285230c,
title = "Evidence Refuting the Existence of Autoimmune/Autoinflammatory Syndrome Induced by Adjuvants (ASIA)",
abstract = "Autoimmune/autoinflammatory syndrome induced by adjuvants (ASIA) was described in 2011. Over time the condition and its triggers have broadened to include several autoimmune disorders, the macrophagic myofasciitis syndrome, the Gulf war syndrome, the sick building syndrome, siliconosis, and the chronic fatigue syndrome. The aluminum-containing adjuvants in the hepatitis B vaccine and the human papillomavirus vaccine in particular have been stated to be the major causes of the disorder. Here, we review the specificity of the diagnostic criteria for ASIA. We also examine relevant human data, pertaining to causation, particularly from patients undergoing allergen-specific immunotherapy (IT). Patients undergoing allergen-specific IT receive 100 to 500 times more injected aluminum over 3 to 5 years, compared with hepatitis B and human papillomavirus vaccine recipients. In a large pharmacoepidemiological study, in contrast to case series of ASIA, patients receiving aluminum-containing allergen IT preparations were shown to have a lower incidence of autoimmune disease. In another clinical trial, there were no increases in exacerbations in a cohort of patients with systemic lupus erythematosus immunized with the hepatitis B vaccine. Current data do not support the causation of ASIA by vaccine adjuvants containing aluminum, which should be of reassurance to patients undergoing routine immunizations as well as to those undergoing allergen-specific IT.",
keywords = "ASIA, Autoimmunity, SLE, Vaccines",
author = "Rohan Ameratunga and David Gillis and Michael Gold and Allan Linneberg and Elwood, {J. Mark}",
year = "2017",
doi = "10.1016/j.jaip.2017.06.033",
language = "English",
volume = "5",
pages = "1551--1555.e1",
journal = "The Journal of Allergy and Clinical Immunology: In Practice",
issn = "2213-2198",
publisher = "Elsevier",
number = "6",

}

RIS

TY - JOUR

T1 - Evidence Refuting the Existence of Autoimmune/Autoinflammatory Syndrome Induced by Adjuvants (ASIA)

AU - Ameratunga, Rohan

AU - Gillis, David

AU - Gold, Michael

AU - Linneberg, Allan

AU - Elwood, J. Mark

PY - 2017

Y1 - 2017

N2 - Autoimmune/autoinflammatory syndrome induced by adjuvants (ASIA) was described in 2011. Over time the condition and its triggers have broadened to include several autoimmune disorders, the macrophagic myofasciitis syndrome, the Gulf war syndrome, the sick building syndrome, siliconosis, and the chronic fatigue syndrome. The aluminum-containing adjuvants in the hepatitis B vaccine and the human papillomavirus vaccine in particular have been stated to be the major causes of the disorder. Here, we review the specificity of the diagnostic criteria for ASIA. We also examine relevant human data, pertaining to causation, particularly from patients undergoing allergen-specific immunotherapy (IT). Patients undergoing allergen-specific IT receive 100 to 500 times more injected aluminum over 3 to 5 years, compared with hepatitis B and human papillomavirus vaccine recipients. In a large pharmacoepidemiological study, in contrast to case series of ASIA, patients receiving aluminum-containing allergen IT preparations were shown to have a lower incidence of autoimmune disease. In another clinical trial, there were no increases in exacerbations in a cohort of patients with systemic lupus erythematosus immunized with the hepatitis B vaccine. Current data do not support the causation of ASIA by vaccine adjuvants containing aluminum, which should be of reassurance to patients undergoing routine immunizations as well as to those undergoing allergen-specific IT.

AB - Autoimmune/autoinflammatory syndrome induced by adjuvants (ASIA) was described in 2011. Over time the condition and its triggers have broadened to include several autoimmune disorders, the macrophagic myofasciitis syndrome, the Gulf war syndrome, the sick building syndrome, siliconosis, and the chronic fatigue syndrome. The aluminum-containing adjuvants in the hepatitis B vaccine and the human papillomavirus vaccine in particular have been stated to be the major causes of the disorder. Here, we review the specificity of the diagnostic criteria for ASIA. We also examine relevant human data, pertaining to causation, particularly from patients undergoing allergen-specific immunotherapy (IT). Patients undergoing allergen-specific IT receive 100 to 500 times more injected aluminum over 3 to 5 years, compared with hepatitis B and human papillomavirus vaccine recipients. In a large pharmacoepidemiological study, in contrast to case series of ASIA, patients receiving aluminum-containing allergen IT preparations were shown to have a lower incidence of autoimmune disease. In another clinical trial, there were no increases in exacerbations in a cohort of patients with systemic lupus erythematosus immunized with the hepatitis B vaccine. Current data do not support the causation of ASIA by vaccine adjuvants containing aluminum, which should be of reassurance to patients undergoing routine immunizations as well as to those undergoing allergen-specific IT.

KW - ASIA

KW - Autoimmunity

KW - SLE

KW - Vaccines

U2 - 10.1016/j.jaip.2017.06.033

DO - 10.1016/j.jaip.2017.06.033

M3 - Review

C2 - 28888842

AN - SCOPUS:85028766525

VL - 5

SP - 1551-1555.e1

JO - The Journal of Allergy and Clinical Immunology: In Practice

JF - The Journal of Allergy and Clinical Immunology: In Practice

SN - 2213-2198

IS - 6

ER -

ID: 187622065